NephU

IgA Nephropathy - From Pathogenesis to Current Management
2025-03-12 18:00 - 21:00 (America/Los_Angeles) | Ocean Prime Family Restaurant, 107 SW Interstate Ave, Chehalis, WA, 98532, United States
About This Event

Living Kidney Donation: One Solution for Patients with End-Stage Kidney Disease
This presentation is an overview of IgA Nephropathy (IgAN), the most common primary glomerular nephropathy worldwide. During this presentation you will learn the clinical presentation, diagnosis, prognosis, and unmet treatment needs of IgAN. You will then take a deep dive into the current understanding of IgAN pathogenesis including the four hit cascade and the key role B-cells and APRIL (A PRoliferation-Inducing Ligand) play in driving disease progression.

Location

Featuring

Sara Nam, PharmD, BCCCP
Nephrology Medical Science Liaison

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Sara Nam, PharmD, BCCCP is a Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) covering the Pacific Northwest Territory. Dr. Nam earned her Doctorate in Pharmacy from the University of Oklahoma and completed her postgraduate general pharmacy residency at Oklahoma State University Medical Center and her postgraduate critical care pharmacy residency at Memorial Hermann-Texas Medical Center. Prior to joining Otsuka, Dr. Nam practiced as an Emergency Medicine Pharmacy Specialist at the Methodist Health System in Dallas, TX and as a Portfolio Executive for Pharmacy Sourcing at Vizient, Inc. Dr. Nam holds a board certification in critical care pharmacotherapy.

Sara Nam, PharmD, BCCCP is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

IgA Nephropathy - From Pathogenesis to Current Management
2025-03-13 18:30 - 21:00 (America/Los_Angeles) | Maggiano’s Little Italy, 3055 Olin Ave Suite 1000, San Jose, California, 95128, United States
About This Event

Living Kidney Donation: One Solution for Patients with End-Stage Kidney Disease
This presentation is an overview of IgA Nephropathy (IgAN), the most common primary glomerular nephropathy worldwide. During this presentation you will learn the clinical presentation, diagnosis, prognosis, and unmet treatment needs of IgAN. You will then take a deep dive into the current understanding of IgAN pathogenesis including the four hit cascade and the key role B-cells and APRIL (A PRoliferation-Inducing Ligand) play in driving disease progression.

Location

Featuring

Sushma Shiravanthe, PharmD, BCPS
Nephrology Medical Science Liaison

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Sushma Shiravanthe, PharmD, BCPS, is a Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) covering Northern California. Dr. Shiravanthe earned her BS in Brain, Behavior, and Cognitive Science and Doctorate of Pharmacy degrees from the University of Michigan in Ann Arbor, MI. She completed residency training at Ascension St. Vincent Anderson in Anderson, IN during which time she also earned a teaching certificate from Purdue University College of Pharmacy. Dr. Shiravanthe is Board Certified in Pharmacotherapy (BCPS) and is a licensed pharmacist in Indiana and California. Prior to joining Otsuka, Dr. Shiravanthe worked as a clinical pharmacist at Ascension St. Vincent Anderson for 2.5 years, and as a clinical pharmacy specialist at the Department of Veterans Affairs Palo Alto Healthcare System for 3 years. During this time, she also served as a preceptor for the pharmacy residency program clinical teaching skills, grand rounds, and clinical research rotations. Her clinical practice experience includes internal medicine, cardio-renal diseases, infectious diseases, and geriatrics.

Sushma Shiravanthe, PharmD, BCPS is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

The Immunomodulating Role of B-cells in IgA Nephropathy – Focus on APRIL
2025-04-08 12:00 - 13:00 (America/New_York)
Thank you for attending, we hope you enjoyed this webinar.
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Living Kidney Donation: One Solution for Patients with End-Stage Kidney Disease
Background: IgA Nephropathy (IgAN) is the most common form of glomerulonephritis and a leading cause of End-Stage Kidney Disease (ESKD)1. Despite its prevalence, a major challenge in managing IgAN lies in the striking heterogeneity of disease progression, with patients facing a 10-year risk of ESKD ranging from 5% to 60%1. Recent advances in immunology have illuminated the central role of B cells in IgAN pathogenesis, particularly their contribution to the production of aberrantly glycosylated IgA1 (Gd-IgA1)2. This webinar will explore how B-cell biology, including the role of APRIL (A Proliferation-Inducing Ligand), informs our understanding of IgAN and opens new avenues for therapeutic intervention.

Did You Know?

APRIL is a key regulator of B-cell survival and IgA production, and elevated serum levels of APRIL have been linked to worse renal outcomes in IgAN patients3.

Why Attend This Webinar?

This session will provide a comprehensive overview of the immunomodulating role of B cells in IgAN, from basic biology to clinical implications. Attendees will gain insights into the multi-hit process of IgAN pathogenesis, the role of B cells in generating pathogenic Gd-IgA1, and the emerging therapeutic strategies targeting immune pathways like APRIL.

What You Will Learn

The fundamentals of B-cell biology and its connection to immune regulation, IgA production, and IgAN pathogenesis.
The four-hit process in IgAN, including the role of B cells in producing Gd-IgA1.
The physiologic role of APRIL in B-cell maturation, IgA production, and its significance in IgAN progression.
Emerging clinical evidence supporting the targeting of APRIL and other immune pathways in IgAN treatment.

References:

Barbour SJ, et al. Evaluating a New International Risk-Prediction Tool in IgA Nephropathy. JAMA Intern Med. 2019 Jul 1;179(7):942-952. Accessed 2/3/25
Popova A, et al. IgA class-switched CD27-CD21+ B cells in IgA nephropathy. Nephrol Dial Transplant. 2024 Jul 17:gfae173 . Epub ahead of print. Accessed 2/3/25
Zhai YL, et al. Increased APRIL Expression Induces IgA Abnormal Glycosylation in IgA Nephropathy. Medicine (Baltimore). 2016;95(1):e3099. Accessed 2/3/25

Speakers

Maria-Gabriela Velez, MD, PhD
Nephrologist, Kidney Associates of Colorado

Maria-Gabriela Velez, M.D., Ph.D, is a trained physician scientist with a special interest in diabetic kidney disease and inflammatory/autoimmune diseases of the kidney.
Dr. Velez completed

medical training and obtained her doctorate in immunology at the University of Colorado School of Medicine. Her doctoral thesis was focused on B cell biology; more specifically B cell development, negative selection and differentiation, under the mentorship of Dr. Roberta Pelanda.
She then completed her training in internal medicine and her fellowship in nephrology at Stanford University.
Dr. Velez returned to Colorado to join Kidney Associates of Colorado in 2015. She uses her extensive medical experience and Spanish-speaking skills to provide comprehensive treatment options and dialysis education to the Hispanic community. Dr. Velez has volunteered and worked in community health clinics, having been recognized for helping increase access to health care.

Moderators

Sachin Hajarnis, PhD
Nephrology Medical Science Director

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Sachin Hajarnis, PhD is a Senior Medical Science Liaison at Otsuka Pharmaceuticals. Dr Hajarnis has a Bachelors and Masters in Life Sciences from University of Mumbai, India. He obtained a PhD in Biochemistry and Molecular Biology from Colorado State University. Dr Hajarnis joined the University of Texas Southwestern Medical school in Dallas, as a post-doctoral fellow in the department of Nephrology where he performed basic research on various aspects of Polycystic Kidney Disease (PKD). He continued his studies on the role of micro-RNAs in PKD as a Research Scientist for several years before joining his current position at Otsuka.

Josh Gariboldi, PharmD, BCPS
Nephrology Senior Medical Science Liaison

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Josh Gariboldi, PharmD, BCPS joined Otsuka in January 2021 and is a Senior Medical Science Liaison on our Nephrology East Team, covering the Carolinas and Tennessee. Dr Gariboldi earned his Doctor of Pharmacy degree from the University of Florida in 2012. He has more than eight years of experience as a clinical pharmacist in both the community and hospital settings, most recently at Bon Secours Mercy Health St. Francis Hospital in Greenville, SC. Dr Gariboldi served as a preceptor with Presbyterian College School of Pharmacy, where he instructed students on Advanced Pharmacy Practice rotations. He holds board certifications in both pharmacotherapy and medical affairs.

Dr. Maria-Gabriela Velez is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc.

Dr. Josh Gariboldi and Dr. Sachin Hajarnis are employees of Otsuka Pharmaceutical Development & Commercialization, Inc.

Disclaimer: The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional.
February 2025 US.CORP.X.25.00019

Registration

Related Resources

Biomarkers in IgA Nephropathy

On-Demand Webinar December 3, 2025

This webinar will focus on the current biomarker landscape as well as novel biomarkers that are currently being studied. The webinar will also focus on why biomarkers are needed and…

Basic Anatomy of Glomerulus & IgAN Pathology

Infographic November 7, 2025

This infographic will give an opportunity to learn more about where IgA deposits in the kidney and how the depositions impact the patient’s outcome.

Navigating the Differential Diagnosis of Proteinuria with an Emphasis on IgA Nephropathy

On-Demand Webinar October 3, 2025

To enhance your understanding of the presentation, differential diagnosis, and workup of proteinuria. There is also the opportunity to explore the pathophysiology and risk of progression of IgA nephropathy and…

IgA Nephropathy - From Pathogenesis to Current Management
2025-04-16 18:00 - 20:00 (America/Denver) | Vintage 423, 8000 Paseo Del Norte Drive,, Albuquerque, NM, 87122, United States
About This Event

Living Kidney Donation: One Solution for Patients with End-Stage Kidney Disease
This presentation is an overview of IgA Nephropathy (IgAN), the most common primary glomerular nephropathy worldwide. During this presentation you will learn the clinical presentation, diagnosis, prognosis, and unmet treatment needs of IgAN. You will then take a deep dive into the current understanding of IgAN pathogenesis including the four hit cascade and the key role B-cells and APRIL (A PRoliferation-Inducing Ligand) play in driving disease progression.

Location

Featuring

Sachin Hajarnis, PhD
Nephrology Medical Science Director

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Sachin Hajarnis, PhD is a Senior Medical Science Liaison at Otsuka Pharmaceuticals. Dr Hajarnis has a Bachelors and Masters in Life Sciences from University of Mumbai, India. He obtained a PhD in Biochemistry and Molecular Biology from Colorado State University. Dr Hajarnis joined the University of Texas Southwestern Medical school in Dallas, as a post-doctoral fellow in the department of Nephrology where he performed basic research on various aspects of Polycystic Kidney Disease (PKD). He continued his studies on the role of micro-RNAs in PKD as a Research Scientist for several years before joining his current position at Otsuka.

Sachin Hajarnis, PhD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

IgA Nephropathy - From Pathogenesis to Current Management
2025-04-23 18:30 - 20:00 (America/Los_Angeles) | Greensleeves Steakhouse, 220 Orange St, Redlands, CA, 92374, United States
About This Event

Living Kidney Donation: One Solution for Patients with End-Stage Kidney Disease
This presentation is an overview of IgA Nephropathy (IgAN), the most common primary glomerular nephropathy worldwide. During this presentation you will learn the clinical presentation, diagnosis, prognosis, and unmet treatment needs of IgAN. You will then take a deep dive into the current understanding of IgAN pathogenesis including the four hit cascade and the key role B-cells and APRIL (A PRoliferation-Inducing Ligand) play in driving disease progression.

Location

Featuring

Marla Dallal, PharmD, RPH
Nephrology Senior Medical Science Liaison

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Marla Dallal, PharmD, RPH is a Medical Science Liaison at Otsuka Pharmaceutical Development and Commercialization covering Southern California. She earned her Doctor of Pharmacy degree from the University of Southern California, School of Pharmacy in Los Angeles. While in pharmacy school, Dr Dallal pursued various clinical internships within the acute care and ambulatory care settings at Cedars-Sinai Medical Center and Kaiser Permanente. Prior to joining Otsuka, Dr Dallal held various positions within Medical Affairs at Amgen Inc covering the cardiometabolic and nephrology therapeutic areas. She also served as a preceptor at Amgen Inc, where she instructed pharmacy students on Advanced Pharmacy Practice rotations. She is currently licensed as a pharmacist in the state of California with the National Association Board of Pharmacy.

Marla Dallal, PharmD, RPH is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

IgA Nephropathy - From Pathogenesis to Current Management
2025-04-24 18:30 - 21:00 (America/Los_Angeles) | Paul Martin’s American Grill, 101 Hillsdale Shopping Ctr, San Mateo, California, 94403, United States

4-Part IgAN Experience: An Immersive, Interactive Dinner Series Brought to You by NephU
2025-05-06 18:30 - 21:00 (America/New_York) | Ruth’s Chris Steak House – Maywood, 83 W Spring Valley Ave L-6, Maywood, New Jersey, 07607, United States
About This Event

Living Kidney Donation: One Solution for Patients with End-Stage Kidney Disease
Step into an educational journey designed to deepen your understanding of IgA Nephropathy (IgAN) through an engaging, multi-format learning experience—powered by cutting-edge tools and real-world insights.

Here’s what to expect across the evening’s four parts:

Apple Vision Pro Interactive Module

Experience a groundbreaking new way to learn about IgAN. Through Apple Vision Pro, dive into the pathogenic cascade that leads to kidney injury and explore the role of APRIL, a key initiating and sustaining factor in IgAN. This immersive mixed-reality module puts disease education right before your eyes—literally.

Journal Club: RaDaR Literature Review

Review long-term outcomes from the UK’s National Registry of Rare Kidney Diseases (RaDaR) and explore how short-term changes in proteinuria and eGFR slope relate to lifetime kidney failure risk. Gain insights into evolving markers for disease progression and their impact on patient care.

Patient Case Deep Dive: Persistent Proteinuria

IgAN previously has been considered a benign disease, particularly for patients below the target proteinuria level of <1 g/d. However, studies suggest that the risk of progression to ESKD cannot be ignored, even for patients traditionally considered low risk. Join us for a patient case discussion regarding persistent proteinuria!

Resource Showcase

Browse a curated set of NephU-approved educational tools, infographics, and simulators to support HCP education beyond the dinner. Connect with MSLs to get the most from these high-value resources.

Location

Featuring

Max Hyams, PharmD, RPh
Nephrology Medical Science Liaison

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Max Hyams, PharmD, RPh, is a Nephrology Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization (OPDC) covering New Jersey. He earned his Doctorate of Pharmacy from Albany College of Pharmacy and Health Sciences in Albany, New York. Prior to joining Otsuka, he was a Global Pharmacovigilance Case Processor in Specialty Medicine at Bayer, working closely with colleagues in Brazil and Germany. Prior to that, he was a Pharmacy Manager for CVS, working in the highest volume, 24-hour stores in Northern New Jersey, and has experience working for an independent pharmacy specializing in fertility medications. He is currently licensed as a pharmacist in New Jersey and resides in Hoboken, New Jersey.

Andrea Mohindra, PharmD
Nephrology Medical Science Liaison

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Andrea Mohindra, PharmD, is a Nephrology Medical Science Liaison covering New York City & Long Island. She earned her PharmD at the University of Rhode Island in South Kingstown, RI. Prior to joining Otsuka in 2021, Dr Mohindra held various leadership roles in retail pharmacy for 15 years in the NJ and NYC regions. Most recently, she held the role of Doctor Partnership Manager for a retail pharmacy startup company and worked closely with Psychiatrists and Migraine Specialists. She is currently licensed in New Jersey and New York state.

Kartik Kalra, MD
Clinical Associate in Nephrology, Associate Program Director of Nephrology Fellowship training program – Geisinger Medical Center; Assistant Professor of Medicine – Geisinger Commonwealth School of Medicine

Kartik Kalra, MD, is a Clinical Associate in Nephrology and serves as the Associate Program Director of the Nephrology Fellowship training program at Geisinger Medical

in Danville, PA. Additionally, he is an Assistant Professor of Medicine at Geisinger Commonwealth School of Medicine. Dr. Kalra completed his internal medicine residency at St. Peter’s University Hospital, Rutgers, NJ, and then pursued a nephrology fellowship at the University of Pittsburgh Medical Center. He further specialized in glomerular disease through GLOMCON fellowship, where he currently acts as a faculty mentor. His primary areas of interest include glomerular disease, peritoneal dialysis, ICU nephrology, and electrolyte abnormalities. He has published peer-reviewed articles and presented numerous posters at national and international conferences. Dr. Kalra has been honored with the David R. Gutknecht Award for excellence in clinical teaching at Geisinger and is featured on the Internal Medicine Faculty Honor Roll. He is a senior member of the Geisinger Academy of Educators and a Fellow of both the American Society of Nephrology and the National Kidney Foundation.

Max Hyams, PharmD, RPh and Andrea Mohindra, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Kartik Kalra, MD is a Community Advisor for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

IgA Nephropathy - From Pathogenesis to Current Management
2025-05-08 18:30 - 21:00 (America/North_Dakota/New_Salem) | Grotto Ristorante, 4715 Westheimer Rd, Houston, TX, 77027, United States
About This Event

Living Kidney Donation: One Solution for Patients with End-Stage Kidney Disease
This presentation is an overview of IgA Nephropathy (IgAN), the most common primary glomerular nephropathy worldwide. During this presentation you will learn the clinical presentation, diagnosis, prognosis, and unmet treatment needs of IgAN. You will then take a deep dive into the current understanding of IgAN pathogenesis including the four hit cascade and the key role B-cells and APRIL (A PRoliferation-Inducing Ligand) play in driving disease progression.

Location

Featuring

Bolanle Soyombo, PharmD, BCACP
Medical Science Liaison, Nephrology

Dr. Bolanle Soyombo is a Medical Science Liaison at Otsuka, board-certified in ambulatory care. She holds a PharmD from the University of Houston and has managed chronic diseases at Ochsner Health and Devoted Health.

Bolanle Soyombo is a medical science liaison at Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr. Soyombo received her doctorate in pharmacy from the University of Houston College of Pharmacy in 2018 and went on to complete an ambulatory care focused PGY1 residency at Xavier University of Louisiana. Prior to joining Otsuka, Dr. Soyombo worked for Ochsner Health in the Digital Medicine Department where she independent managed chronic diseases for patients in the greater New Orleans Area. She went on to work for Devoted Health where she broadened her reach to patient populations across 7 states in the US. Dr. Soyombo has a passion for disease state management and education. She is a board-certified ambulatory care pharmacist.

Bolanle Soyombo, PharmD, BCACP is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

From Diagnosis to Management in IgA Nephropathy: How Health Literacy Shapes the Patient Journey
2025-05-14 12:00 - 13:00 (America/New_York)
Thank you for attending, we hope you enjoyed this webinar.
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Living Kidney Donation: One Solution for Patients with End-Stage Kidney Disease
Background:

Health literacy is defined by the Institute of Medicine as the degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed to make informed health decisions.1 Low health literacy affects 25% of patients with CKD and is associated with increased morbidity and death.2 The annual global incidence of IgA nephropathy (IgAN) is 2.5 cases/100,000; however this varies by region and ethnicity.3 The annual US incidence is around 1.29/100,000 persons.4

Did You Know?

Nearly 9 in 10 adults in America have trouble understanding some or all the health information they receive from HCPs or publicly.5
Many patients with IgAN have lost nearly 50% of their kidney function at the time of diagnosis.6

Why Attend This Webinar?

Learn about health literacy and how it impacts patients with CKD including IgAN. Dr. Velez will share her expertise as a nephrologist treating patients with IgAN as well as discuss some of the challenges in her own practice. We will discuss how differing levels of health literacy can impact the patient journey during presentation, diagnosis, prognosis, and management, including access to care.

What You Will Learn

What is health literacy and how it relates to kidney disease and the patient journey in IgAN.
Clinical features, diagnosis, and prognosis of IgAN and how differing levels health literacy can impact patient outcomes.
How healthcare professionals can support patients with differing levels of health literacy.

References:

Jain D, et al. World J Nephrol. 2016;5(2):147-151.
Campbell ZC, et al. Cochrane Database Syst Rev. 2022;12(12):CD012026. March 2025 US.CORP.X.25.00051
McGrogan A et al. Nephrol Dial Transplant. 2011 ;26(2) :414-430
Kwon CS et al. J Health Econ Outcomes Res. 2021;8(2):36-45
US Department of Health and Human Services (DHHS), Office of Disease Prevention and Health Promotion. National action plan to improve health literacy. Washington, DC: Author. https://odphp.health.gov/sites/default/files/2019-09/Health_Literacy_Action_Plan.pdf. Published 2010. Assessed 3/18/25
Kwon CS, et al. J Health Econ Outcomes Res. 2021;8(2):36-45

Speakers

Maria-Gabriela Velez, MD, PhD
Nephrologist, Kidney Associates of Colorado

Maria-Gabriela Velez, M.D., Ph.D, is a trained physician scientist with a special interest in diabetic kidney disease and inflammatory/autoimmune diseases of the kidney.
Dr. Velez completed

medical training and obtained her doctorate in immunology at the University of Colorado School of Medicine. Her doctoral thesis was focused on B cell biology; more specifically B cell development, negative selection and differentiation, under the mentorship of Dr. Roberta Pelanda.
She then completed her training in internal medicine and her fellowship in nephrology at Stanford University.
Dr. Velez returned to Colorado to join Kidney Associates of Colorado in 2015. She uses her extensive medical experience and Spanish-speaking skills to provide comprehensive treatment options and dialysis education to the Hispanic community. Dr. Velez has volunteered and worked in community health clinics, having been recognized for helping increase access to health care.

Moderators

Lisa Voigt, PharmD, BCPS, BCCCP
Nephrology Senior Medical Science Liaison

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Lisa Voigt, PharmD, BCPS, BCCCP is a PharmD who works as a Senior Medical Science Liaison in Nephrology with Otsuka Pharmaceutical Development & Commercialization, Inc. Prior to joining Otsuka in 2019, Dr Voigt practiced as a Medical Intensive Care Unit and Surgical Intensive Care Unit Pharmacist for 15 years at a tertiary medical center in Buffalo, NY. She earned her Bachelor of Science degree in Pharmaceutics and PharmD from the SUNY Buffalo School of Pharmacy and Pharmaceutical Sciences. She completed a Post-Graduate year 1 Pharmacy Residency and Post-Graduate year 2 Critical Care/Emergency Medicine Pharmacy Residency at the University of Rochester Medical Center in Rochester, NY. Dr Voigt is a Past-President of the New York State Council of Health-system Pharmacists and has served on the Board of Directors for the past 10 years. She is also Past-President of the Western New York Society of Health-system Pharmacists. She is an Adjunct Assistant Professor at SUNY Buffalo, School of Pharmacy and Pharmaceutical Sciences. Dr Voigt holds board certifications in pharmacotherapy as well as critical care pharmacotherapy.

Maria-Gabriela Velez, MD, PhD is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc.

Lisa Voigt, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.

Disclaimer: The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional.
March 2025 US.CORP.X.25.00051

Registration

Related Resources

Biomarkers in IgA Nephropathy

On-Demand Webinar December 3, 2025

This webinar will focus on the current biomarker landscape as well as novel biomarkers that are currently being studied. The webinar will also focus on why biomarkers are needed and…

Basic Anatomy of Glomerulus & IgAN Pathology

Infographic November 7, 2025

This infographic will give an opportunity to learn more about where IgA deposits in the kidney and how the depositions impact the patient’s outcome.

Navigating the Differential Diagnosis of Proteinuria with an Emphasis on IgA Nephropathy

On-Demand Webinar October 3, 2025

To enhance your understanding of the presentation, differential diagnosis, and workup of proteinuria. There is also the opportunity to explore the pathophysiology and risk of progression of IgA nephropathy and…

IgA Nephropathy - From Pathogenesis to Current Management
2025-05-21 18:00 - 20:00 (America/Los_Angeles) | Fleming’s Prime Steakhouse & Wine Bar Newport Beach, 445 Newport Center Dr, Newport Beach, California, 92660, United States

IgA Nephropathy - From Pathogenesis to Current Management
2025-05-28 18:00 - 20:00 (America/Los_Angeles) | Mastro’s Steakhouse – CA, 2087 E Thousand Oaks Blvd, Thousand Oaks, California, 91362, United States

Transition of Care from Pediatric to Adult Nephrology Webinar
2025-06-18 12:00 - 13:00 (America/New_York)
Thank you for attending, we hope you enjoyed this webinar.
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Living Kidney Donation: One Solution for Patients with End-Stage Kidney Disease
Did You Know?

Adolescents and young adults with chronic disease are at risk for treatment nonadherence, loss to follow-up, and poor health outcomes due to potential personal and systemic barriers that may inhibit a successful transition from pediatric to adult care.1

Why Attend This Webinar?

During this webinar, Dr. McCune and Dr. Greco will discuss the process of transitioning from pediatric to adult nephrology care. They will discuss the process and best practices associates with transitioning from pediatric to adult nephrology care. Additionally, they will discuss considerations for a successful transition and potential barriers to a successful transition.

What You Will Learn

Review the core principles of nephrology care transitioning in younger patients
Discuss current recommendations for transitioning patients with CKD from pediatric to adult nephrology
Identify factors associated with successful transfer from pediatric to adult nephrology

References:

Harambat J, et al. Pediatr Nephrol. 2023;38(5):1389-1393.

Accessed 1/6/2025

Speakers

Thomas McCune, MD, FACP
Associate Professor, Chair of the Division of Nephrology, & Fellowship Program Director at Eastern Virginia Medical School; Director, Hereditary Kidney Disease Clinic Partner, Nephrology Associates of Tidewater, Norfolk, Virginia*

Dr.McCune received his medical degree and completed his internal medicine residency at Eastern Virginia Medical School. He then went on to complete his Nephrology and

Fellowship training at Vanderbilt University.
Dr. McCune currently is a partner at Nephrology Associates of Tidewater in Norfolk, Virginia where he commonly treats patients with diabetes complications, severe hypertension and genetic disorders such as polycystic kidney disease. Dr. McCune serves as the Primary Physician for the Pancreas Transplant Program at Sentara Norfolk General Hospital and Medical Director of Fresenius Kidney Care of Greater Norfolk. In addition, Dr. McCune is an Associate Professor of Medicine, Chair of the Division of Nephrology, and Fellowship Program Director at Eastern Virginia Medical School in Norfolk. Beyond caring for his patients, Dr. McCune has impressively served his country for over 30 years in the Army Reserve and National Guard. In 2016 he retired as a Colonel in the Medical Corps.

Jessica Greco, MD
Nephrologist, the Ohio State University Wexner Medical Center; Assistant Professor of Medicine-Nephrology at Ohio State University College of Medicine

Dr. Greco received her medical degree at MUSOM in Huntington, WV and completed her residency at Geisinger Medical Center. She then went on to complete

Med-Peds Nephrology Fellowship at Ohio State University and Nationwide children’s Hospital in Columbus, OH.
Dr. Greco is currently a Nephrologist at the Ohio State University Wexner Medical Center and an Assistant Professor of Medicine-Nephrology at Ohio State University College of Medicine. Dr. Greco leads and manages a Glomerular Disease Transition clinic and a Transplant Transition clinic and has provided a presentation at the Ohio Symposium of the National Kidney Foundation titled “Helping Pediatric Patients Transition to Adult Care in ESRD and Transplant.”

Moderators

Michael Filsinger, MPA, PA-C
Nephrology Medical Science Liaison

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Michael Filsinger, MPA, PA-C is a Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Michael earned his Bachelor of Health Care Sciences as well as Master of Physician Assistant at Duquesne University in Pittsburgh, PA. Following his graduate training, Michael went on to complete a Pediatric Surgery Residency at Children’s National Medical Center in Washington, DC Prior to joining Otsuka, Michael spent the last 15 years working in solid organ transplant in Charlotte, NC where he developed a passion for improving the care of patients with renal disease and ESKD.

Kimberly Means, PharmD, BCCCP, BSN, RN
Medical Science Liaison

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Kimberly Means, PharmD, BCCCP, BSN, RN, is a Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Means earned her B.S. in Nursing (BSN) and her Doctor of Pharmacy (PharmD) from Virginia Commonwealth University (VCU) in Richmond, Virginia. She completed a PGY-1 Pharmacy Practice Residency and a PGY-2 Critical Care Residency at VCU Health in Richmond, Virginia. Prior to joining Otsuka, she worked as a critical care nurse at VCU Health, a Critical Care Clinical Pharmacist at Henrico Doctors’ Hospital, and a Clinical Pharmacist in Surgical Services at VCU Health. During her time as a Clinical Assistant Professor at the VCU School of Pharmacy and VCU Health she served as a preceptor for pharmacy students and pharmacy residents. Dr Means is a Board Certified Critical Care Pharmacotherapy Specialist (BCCCP).

Dr. Thomas McCune is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc.

Dr. Jessica Greco is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc.

Dr. Kimberly Means is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.

Michael Filsinger is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.

Disclaimer: The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional.
January 2025 US.CORP.X.24.00358

Registration

Related Resources

4 Part IgAN Experience
2025-07-08 18:00 - 20:00 (America/Los_Angeles) | UCLA Meyer & Renee Luskin Conference Center, 425 Westwood Plaza, Los Angeles, California, 90095, United States
About This Event

Living Kidney Donation: One Solution for Patients with End-Stage Kidney Disease
An innovative, four-part educational experience designed to immerse healthcare professionals in the evolving landscape of IgA Nephropathy (IgAN) through interactive technology, evidence-based literature, real-world case studies, and high-impact educational tools.
Program Overview
Participants will engage in a dynamic dinner event that blends interactive learning with case-based discussions. The program is modular, allowing requesters to select their preferred literature topic and patient case focus, while the other elements remain consistent and highly engaging.

B-Cell Biology and the Role of Cytokines in B-Cell Modulation
The physiological function of APRIL in B-cell regulation, and the growing body of evidence supporting APRIL inhibition as a potential therapeutic approach.

Literature Review (Journal Club Style)

RaDaR Study: Long-term outcomes in IgAN and the predictive value of proteinuria and eGFR decline

Presented by Dr. Mohammad Kamgar

Apple Vision Pro Immersive Experience
Experience disease-state education like never before. Using Apple Vision Pro technology, participants can visually explore:

The 4-hit pathogenic process of IgAN
The role of APRIL in initiating and sustaining kidney injury in IgAN

NephU Resource Station
Hands-on review of pre-approved NephU materials tailored to IgAN, including:​

Interactive simulators​
Infographics​
Educational tools and treatment summaries

Patient Case Study Review
Dive into a real-world case panel discussion on :

Persistent Proteinuria in patients previously considered low risk

Location

Featuring

Marla Dallal, PharmD, RPH
Nephrology Senior Medical Science Liaison

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Marla Dallal, PharmD, RPH is a Medical Science Liaison at Otsuka Pharmaceutical Development and Commercialization covering Southern California. She earned her Doctor of Pharmacy degree from the University of Southern California, School of Pharmacy in Los Angeles. While in pharmacy school, Dr Dallal pursued various clinical internships within the acute care and ambulatory care settings at Cedars-Sinai Medical Center and Kaiser Permanente. Prior to joining Otsuka, Dr Dallal held various positions within Medical Affairs at Amgen Inc covering the cardiometabolic and nephrology therapeutic areas. She also served as a preceptor at Amgen Inc, where she instructed pharmacy students on Advanced Pharmacy Practice rotations. She is currently licensed as a pharmacist in the state of California with the National Association Board of Pharmacy.

Addis Alemayehu, PharmD
Senior Regional Medical Lead

Lama Abdelnour
Assistant Clinical Professor of Medicine, Medical Director – Living Donor Kidney Transplant Program in Westwood.

Dr. Lama Abdelnour is an Assistant Clinical Professor of Medicine and the Medical Director of the Living Donor Kidney Transplant Program in Westwood. Board-certified in

and Internal Medicine, she completed her internal medicine training at the University of Nevada School of Medicine in Las Vegas and her nephrology fellowship at the Keck School of Medicine of USC.
Dr. Abdelnour specializes in general nephrology, with a particular focus on glomerular diseases, including IgA nephropathy, Focal Segmental Glomerulosclerosis (FSGS), membranous nephropathy, minimal change disease, Lupus Nephritis, and ANCA vasculitis. She is also dedicated to optimizing the health and evaluation of living kidney donors.
Beyond her clinical practice, Dr. Abdelnour is a principal investigator on multiple research projects, contributing to advancements in glomerular diseases and living kidney donation.

Mohammad Kamgar

Marla Dallal, PharmD, RPH and Addis Alemayehu, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

A Targeted Approach for Immunoglobulin-A Nephropathy
2025-07-16 12:00 - 13:00 (America/New_York)
Thank you for attending, we hope you enjoyed this webinar.
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Living Kidney Donation: One Solution for Patients with End-Stage Kidney Disease
Background

The majority of patients with IgA nephropathy develop end stage kidney disease (ESKD) within their lifetime.1,2 Despite supportive care, 78% of patients continue to have signs and symptoms, including proteinuria and hematuria, increasing their risk of progression to kidney failure.3 Most current treatments aim to treat the clinical manifestations of CKD, not the underlying cause of IgA nephropathy.1,3

Why Attend This Webinar?

Dr. Srinivasan will discuss the four hit pathogenic process of IgA nephropathy, including the role of galactose deficient immunoglobulin-A1 (Gd-IgA1) and A-proliferation inducing ligand (APRIL). Additional pathways in the disease process will be described and a targeted treatment approach will be presented.

What You Will Learn

The 4-hit process of IgA nephropathy
The pivotal role of APRIL in the immune process of IgA nephropathy
How to address multiple aspects of IgA nephropathy utilizing a targeted management approach

References

Pitcher D, et al. Clin J Am Soc Nephrol. 2023;18(6):727-738.
Wong K, et al. Lancet. 2024;403(10433):1279-1289.
Lafayette R, et al. Poster. International Symposium on IgA Nephropathy. 2023 (poster P-51).

Speaker

Vinay Srinivasan, MD
Assistant Professor of Medicine and Director of Onconephrology, Cooper University Hospital and Cooper Medical School of Rowan University (CMSRU)

Dr. Vinay Srinivasan is an Assistant Professor of Medicine and the Director of Onconephrology at Cooper University Hospital and Cooper Medical School of Rowan University

He completed medical school at the University of Kentucky, Internal Medicine residency at the University of Maryland, Nephrology fellowship and sub-fellowship in Glomerular Disease and Onconephrology both at the University of Pennsylvania. Dr. Srinivasan also earned an MBA from George Washington University.
In his current position, Dr. Srinivasan sees patients with glomerular diseases and cancer related kidney disease. He is involved in medical student education and serves as a primary advisor to M1-M4 students at CMSRU. He serves as a core faculty for the Nephrology fellowship program and focuses on teaching GN and Onconephrology related topics to residents and fellows. Dr. Srinivasan also serves as an investigator for glomerular disease related clinical trials at Cooper University Hospital.

Moderator

Kelly Reed, PhD
Nephrology Senior Medical Science Liaison

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Kelly Reed, PhD, joined Otsuka in 2012 and is currently a Senior Medical Science Liaison on our Nephrology East Team. Dr Reed has collaborated with several national professional organizations and healthcare systems providing educational presentations on hyponatremia and Autosomal Dominant Polycystic Kidney Disease (ADPKD). She has been a leader in resource development for the MSL team, co-led the nephrology MSL new hire training program during expansion and served as a mentor to several MSL new hires. Dr Reed earned her doctorate from Virginia Commonwealth University in Richmond, Virginia and completed her clinical internship at the Mailman Center for Child Development in Miami, Florida, followed by a two year fellowship at Cincinnati Children’s Hospital Medical Center.

Vinay Srinivasan is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc.

Kelly Reed is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.

Disclaimer: The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional.
June 2025 US.CORP.X.25.00103

Registration

Related Resources

IgA Nephropathy: Pathogenesis, the Role of APRIL and the 4-Hit Process, and a Patient Case Study
2025-08-14 18:00 - 20:00 (America/Chicago) | The Capital Grille – Plano, 7300 Dallas Parkway, Texas, 75024, United States
About This Event

Living Kidney Donation: One Solution for Patients with End-Stage Kidney Disease
IgA Nephropathy: Pathogenesis, the Role of APRIL and the 4-Hit Process, and a Patient Case Study – Edgar Lerma, MD

Program Objectives:

The disease burden and current treatment landscape in IgA Nephropathy
Risk factors associated with disease progression in a patient case study
The four-hit process in IgA nephropathy pathogenesis and the role of APRIL

IgAN Simulator – Molly Jansen (MSL)

Here you can get an in-depth look at IgAN pathogenesis and the journeys of patients living with IgAN

Pathogenesis: See the origins of IgAN at the molecular level and how that result sin its progression
Progression: Journey into the profiles of 3 hypothetical patients to see how their IgAN diagnosis was uncovered, and what’s expected in their prognosis

Apple Vision Pro Immersive Experience – Michael Filsinger (MSL)

Experience disease state education like never before. Using Apple Vision Pro technology, participants can visually explore:

The 4-hit pathogenic progress of IgAN
The role of APRIL in initiating and sustaining kidney injury in IgAN

NephU Resource Station – Molly Jansen (MSL)

Check out our educational infographics and grab printed copies to take with you
Learn about our educational tools and treatment summaries

Location

Featuring

Edgar Lerma, MD
Clinical Professor of Medicine, Section of Nephrology, University of Illinois at Chicago

University of Illinois at Chicago*

Edgar Lerma, MD, earned his Doctor of Medicine from the University of Santo Tomas Faculty of Medicine and Surgery in Manila, Philippines. He completed Residency Training in Internal Medicine at UIC/Mercy Hospital and Medical Center, where he also served as Chief Resident. He completed a Fellowship in Nephrology and Hypertension at Northwestern Memorial Hospital, the Feinberg School of Medicine at Northwestern University, and the Veterans Administration Lakeside Medical Center in Chicago, Illinois.
Dr Lerma is a Diplomate in the Subspecialty of Nephrology with the American Board of Internal Medicine. He has authored more than 100 peer-reviewed publications and presentations; notable publications include Current Diagnosis & Treatment: Nephrology & Hypertension, Nephrology Secrets, and Henrich’s Principles and Practice of Dialysis. He has peer reviewed and served on editorial boards for numerous journals, and currently is Associate Editor for International Urology and Nephrology, Clinical Reviews in Bone and Mineral Metabolism, and Journal of Clinical Lipidology.
At present, he holds the rank of Clinical Professor of Medicine with the Section of Nephrology at University of Illinois at Chicago. He serves as the Educational Coordinator for Nephrology with UIC/Advocate Christ Medical Center.
In recognition of his clinical work and expertise, Dr Lerma has been elected to Fellowship of the American College of Physicians, Fellowship of the American Society of Nephrology, Fellowship of the American Heart Association/ Council on Kidney in Cardiovascular Disease, Fellowship of the American Society of Hypertension, Fellowship of the National Lipid Association, Fellowship of the National Kidney Foundation, and Fellowship of the American Society of Diagnostic and Interventional Nephrology. He has also been recognized for teaching and has been the recipient of “Subspecialty Teaching Attending Physician of the Year” in 2006 and “Physician Recognition Award for Excellence in Academics” in 2011 from UIC/Advocate Christ Medical Center Internal Medicine Residency Training Program.
Dr Lerma’s research interests include CKD, hypertension, bone and mineral disorders, and dyslipidemias in CKD.

Molly Jansen, PhD
Nephrology Senior Medical Science Liaison

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Dr Molly Jansen is a Nephrology Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization, Inc. covering South Texas. Molly earned her Doctor of Philosophy degree in Biomedical Science from Wake Forest School of Medicine located in Winston-Salem, NC. While in graduate school, Molly worked as a Business Development Intern at Wake Forest Innovations, fostering the collaborative innovation between industry and the faculty and staff of Wake Forest Baptist Medical Center. After graduate school, Molly did a brief Medical Writing Fellowship with Impact Pharmaceutical Services. Prior to joining Otsuka, Molly worked at Reata Pharmaceuticals, Inc. where she helped to oversee the conduct of clinical trials across a variety of therapeutic areas including nephrology, neurology, and pulmonary, which is where she developed her passion for rare disease.

Michael Filsinger, MPA, PA-C
Nephrology Medical Science Liaison

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Michael Filsinger, MPA, PA-C is a Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Michael earned his Bachelor of Health Care Sciences as well as Master of Physician Assistant at Duquesne University in Pittsburgh, PA. Following his graduate training, Michael went on to complete a Pediatric Surgery Residency at Children’s National Medical Center in Washington, DC Prior to joining Otsuka, Michael spent the last 15 years working in solid organ transplant in Charlotte, NC where he developed a passion for improving the care of patients with renal disease and ESKD.

Edgar Lerma, MD is a speaker for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Molly Jansen, PhD and Michael Filsinger, MPA, PA-C are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

4 Part IgAN Experience
2025-09-16 18:30 - 20:30 (America/New_York) | Aberdeen Barn Steakhouse, 5805 Northampton Blvd, Virginia Beach, VA, 23455, United States
About This Event

Living Kidney Donation: One Solution for Patients with End-Stage Kidney Disease
1. IgA Nephropathy: Early Signs and Symptoms, Disease Burden, and Management
During this presentation you will learn the clinical presentation, diagnosis, prognosis, and unmet treatment needs of IgAN. You will then take a deep dive into the current understanding of IgAN pathogenesis including the four hit cascade and the key role B-cells and APRIL (A PRoliferation-Inducing Ligand) play in driving disease progression.
2. IgAN Simulator
Here you can get an in-depth look at IgAN pathogenesis and the journeys of patients living with IgAN.

Pathogenesis: See the origins of IgAN at the molecular level and how that results in its progression
Progression: Journey into the profiles of 3 hypothetical patients to see how their IgAN diagnosis was uncovered, and what’s expected in their prognosis

3. Apple Vision Pro Immersive Experience
Experience disease-state education like never before. Using Apple Vision Pro technology, participants can visually explore:

The 4-hit pathogenic process of IgAN
The role of APRIL in initiating and sustaining kidney injury in IgAN

4. NephU Resource Station

Check out our educational infographics and grab printed copies to take with you
Learn about our educational tools and treatment summaries

Location

Featuring

Kimberly Means, PharmD, BCCCP, BSN, RN
Medical Science Liaison

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Kimberly Means, PharmD, BCCCP, BSN, RN, is a Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Means earned her B.S. in Nursing (BSN) and her Doctor of Pharmacy (PharmD) from Virginia Commonwealth University (VCU) in Richmond, Virginia. She completed a PGY-1 Pharmacy Practice Residency and a PGY-2 Critical Care Residency at VCU Health in Richmond, Virginia. Prior to joining Otsuka, she worked as a critical care nurse at VCU Health, a Critical Care Clinical Pharmacist at Henrico Doctors’ Hospital, and a Clinical Pharmacist in Surgical Services at VCU Health. During her time as a Clinical Assistant Professor at the VCU School of Pharmacy and VCU Health she served as a preceptor for pharmacy students and pharmacy residents. Dr Means is a Board Certified Critical Care Pharmacotherapy Specialist (BCCCP).

Michael Filsinger, MPA, PA-C
Nephrology Medical Science Liaison

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Michael Filsinger, MPA, PA-C is a Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Michael earned his Bachelor of Health Care Sciences as well as Master of Physician Assistant at Duquesne University in Pittsburgh, PA. Following his graduate training, Michael went on to complete a Pediatric Surgery Residency at Children’s National Medical Center in Washington, DC Prior to joining Otsuka, Michael spent the last 15 years working in solid organ transplant in Charlotte, NC where he developed a passion for improving the care of patients with renal disease and ESKD.

Kimberly Means, PharmD, BCCCP, BSN, RN and Michael Filsinger, MPA, PA-C are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Navigating the Differential Diagnosis of Proteinuria with an Emphasis on IgA Nephropathy
2025-09-17 12:00 - 13:00 (America/New_York)
Thank you for attending, we hope you enjoyed this webinar.
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Living Kidney Donation: One Solution for Patients with End-Stage Kidney Disease
Background

Protein in the urine is a common finding on a urinalysis in clinical practice. This protein comes from the kidney generally because of damage to the glomerulus and/or renal tubules.1 The differential diagnosis of proteinuria can be broad, with the etiology falling into one of three classifications: transient, persistent, and benign.2

Did You Know?

Glomerulonephritis is one cause of persistent proteinuria. The most common glomerulonephritis is IgA nephropathy.3
IgA nephropathy is more prevalent in patients of east Asian descent and is often diagnosed in the second or third decades of life.3
Proteinuria is a prognostic factor in IgA nephropathy, with higher levels associated with faster eGFR decline and progression to kidney failure.4

Why Attend This Webinar?

To enhance your understanding of the presentation, differential diagnosis, and workup of proteinuria. There is also the opportunity to explore the pathophysiology and risk of progression of IgA nephropathy and application of knowledge with hypothetical patient case.

What You Will Learn

Definition of proteinuria and how it is measured
Differential diagnosis of proteinuria
Pathophysiology, diagnosis, and risk of progression in IgA nephropathy

References:

Lewis G, Maxwell AP. Practitioner. 2013;257(1758):19-22, 2-3.
Haider MZ, Aslam A. Proteinuria. 2023 Sep 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 33232060.
Rajasekaran A, Julian BA, Rizk DV. IgA Nephropathy: An Interesting Autoimmune Kidney Disease. Am J Med Sci. 2021 Feb;361(2):176-194. doi: 10.1016/j.amjms.2020.10.003. Epub 2020 Oct 8. PMID: 33309134; PMCID: PMC8577278.
Pitcher D, et al. Clin J Am Soc Nephrol. 2023;18(6):727-738.

Speaker

Maryam Gondal, MBBS/MD
Medical Director, PKD Center of Excellence at Yale New Haven Health; Assistant Professor of Medicine at Yale School of Medicine; Medical Director for incenter and Home Dialysis at DaVita in New Haven, CT

Maryam Gondal, MBBS/MD, is an Assistant Professor of Medicine at Yale School of Medicine. She is a graduate of Aga Khan University in Karachi, Pakistan.

did her Internal Medicine Residency at Indiana University and subsequently completed nephrology fellowship training at Yale University. She is the Medical Director for the PKD Center of Excellence at Yale. Also serves as the Medical Director for in-center and home dialysis at New Haven DaVita. Dr Gondal sees a wide variety of renal pathology; including but not limited to ADPKD, glomerular disease, inherited kidney disease, end stage kidney disease and Geriatric Nephrology.

Moderators

Alf Carroll, DMSc, PA-C
Nephrology Senior Medical Science Liaison

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Alf Carroll, DMSc, PA-C is a Senior Medical Science Liaison at Otsuka Pharmaceutical Development and Commercialization. He earned his Doctor of Medical Science in Healthcare Leadership, Master of Science in Physician Assistant Studies, and Bachelor of Science in Biology from Northeastern University in Boston, Massachusetts. Prior to joining Otsuka, Alf held a position at AstraZeneca Pharmaceuticals working with key health systems in New England, covering the cardiovascular, renal, endocrine, and respiratory areas. Prior to joining industry, he held full time clinical Physician Assistant roles in the Emergency Department at Massachusetts General Hospital and South Shore Hospital, as well as other part time roles in internal medicine in the Boston area.

Dr. Maryam Gondal is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc.

Alf Carroll, DMSc, PA-C is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.

Disclaimer: The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional.
July 2025 US.CORP.X.25.00141

Registration

Related Resources

KDIGO Clinical Practice Guideline for the Evaluation, Management, and Treatment of ADPKD (Part 1)
2025-10-07 12:00 - 13:00 (America/New_York)
Thank you for attending, we hope you enjoyed this webinar.
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Living Kidney Donation: One Solution for Patients with End-Stage Kidney Disease
Background

ADPKD is the most prevalent monogenic kidney disease associated with kidney failure1
An estimated 50% of patients with ADPKD will reach kidney failure by the time they are 60 years old1

Did You Know?

Until recently, there have been no standardized guidelines for the diagnosis and management
of patients with ADPKD
KDIGO convened a panel of multidisciplinary experts to develop clinical practice guidelines to capture their recommendations

Why Attend This Webinar Series?

The goal of this webinar series is to review the 2025 KDIGO Clinical Practice Guideline for the Evaluation, Management, and Treatment of ADPKD

What You Will Learn

Understand the level of evidence and interpret the KDIGO Clinical Practice Guideline for the Evaluation, Management, and Treatment of ADPKD
Explore the different chapters in the KDIGO Clinical Practice Guideline for the Evaluation, Management, and Treatment of ADPKD, including but not limited to, diagnosis and prognosis, management of renal and extrarenal manifestations, and general approaches to management of ADPKD

References:

ADPKD, autosomal dominant polycystic kidney disease; KDIGO, Kidney Disease: Improving Global Outcomes. KDIGO. Kidney Int. 2025;107(2S):S1–S239.

Speaker

Frederic F Rahbari Oskoui, MD
Professor of Medicine, Nephrology, Emory University School of Medicine

Emory University School of Medicine*

Dr Frederic Rahbari is the director of Cystic Kidney Diseases Clinic at Emory University and has been a nephrologist practicing at Emory University Hospital in Atlanta, GA since 2006. Dr Rahbari attended medical school at Université de Bordeaux in France and completed a residency program at the same institution. After moving to the United States, Dr Rahbari did clinical and translational research on oxidative stress at New York Medical College and subsequently redid three years of residency training in internal medicine at St. Vincent Hospital -Columbia University College of Physicians and Surgeons. He has also completed a fellowship in nephrology at Emory University. Dr Rahbari has been a principal investigator in several PKD trials and is a member of the Scientific Advisory Committee of the Polycystic Kidney Disease Foundation.

Moderator

Hannah N. Lambert, PharmD
Nephrology Medical Science Liaison

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Hannah N. Lambert is a Medical Science Liaison at Otsuka Pharmaceutical Development and Commercialization. She earned her Doctor of Pharmacy and completed her clinical residency training at Xavier University of Louisiana College of Pharmacy in New Orleans, LA. Prior to joining Otsuka, Dr Lambert was a clinical pharmacist at Ochsner Health in Digital Medicine.

Frederic F. Rahbari Oskoui is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc.

Hannah Lambert is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.

Disclaimer: The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional.
September 2025 US.CORP.X.25.00190

Registration

Related Resources

Key Takeaways for Clinicians from the KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, & Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Video April 30, 2025

This is the first guideline from KDIGO on a rare kidney disease, and provides healthcare providers, stakeholders, and people living with ADPKD with practical tools to improve diagnosis, care, and…

Hot Topics in Nephrology – Ketogenic Diets for Polycystic Kidney Disease (PKD): Research Insights & Clinical Translation

Audio/Podcast April 10, 2025

In this episode, Dr. Thomas Weimbs discusses ketogenic diets for polycystic kidney disease (PKD), explaining the science behind ketosis and its potential impact.

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Differential Diagnosis Podcast

Audio/Podcast September 16, 2024

Expert speakers will discuss key elements comprising their approach to a differential diagnosis for ADPKD.

KDIGO Clinical Practice Guideline for the Evaluation, Management, and Treatment of ADPKD (Part 2)
2025-10-14 12:00 - 13:00 (America/New_York)
Thank you for attending, we hope you enjoyed this webinar.
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Living Kidney Donation: One Solution for Patients with End-Stage Kidney Disease
Background

ADPKD is the most prevalent monogenic kidney disease associated with kidney failure1
An estimated 50% of patients with ADPKD will reach kidney failure by the time they are 60 years old1

Did You Know?

Until recently, there have been no standardized guidelines for the diagnosis and management
of patients with ADPKD
KDIGO convened a panel of multidisciplinary experts to develop clinical practice guidelines to capture their recommendations

Why Attend This Webinar Series?

The goal of this webinar series is to review the 2025 KDIGO Clinical Practice Guideline for the Evaluation, Management, and Treatment of ADPKD

What You Will Learn

Understand the level of evidence and interpret the KDIGO Clinical Practice Guideline for the Evaluation, Management, and Treatment of ADPKD
Explore the different chapters in the KDIGO Clinical Practice Guideline for the Evaluation, Management, and Treatment of ADPKD, including but not limited to, diagnosis and prognosis, management of renal and extrarenal manifestations, and general approaches to management of ADPKD

References:

ADPKD, autosomal dominant polycystic kidney disease; KDIGO, Kidney Disease: Improving Global Outcomes. KDIGO. Kidney Int. 2025;107(2S):S1–S239.

Speaker

Frederic F Rahbari Oskoui, MD
Professor of Medicine, Nephrology, Emory University School of Medicine

Emory University School of Medicine*

Dr Frederic Rahbari is the director of Cystic Kidney Diseases Clinic at Emory University and has been a nephrologist practicing at Emory University Hospital in Atlanta, GA since 2006. Dr Rahbari attended medical school at Université de Bordeaux in France and completed a residency program at the same institution. After moving to the United States, Dr Rahbari did clinical and translational research on oxidative stress at New York Medical College and subsequently redid three years of residency training in internal medicine at St. Vincent Hospital -Columbia University College of Physicians and Surgeons. He has also completed a fellowship in nephrology at Emory University. Dr Rahbari has been a principal investigator in several PKD trials and is a member of the Scientific Advisory Committee of the Polycystic Kidney Disease Foundation.

Moderator

Hannah N. Lambert, PharmD
Nephrology Medical Science Liaison

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Hannah N. Lambert is a Medical Science Liaison at Otsuka Pharmaceutical Development and Commercialization. She earned her Doctor of Pharmacy and completed her clinical residency training at Xavier University of Louisiana College of Pharmacy in New Orleans, LA. Prior to joining Otsuka, Dr Lambert was a clinical pharmacist at Ochsner Health in Digital Medicine.

Frederic F. Rahbari Oskoui is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc.

Hannah Lambert is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.

Disclaimer: The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional.
September 2025 US.CORP.X.25.00190

Registration

Related Resources

KDIGO Clinical Practice Guideline for the Evaluation, Management, and Treatment of ADPKD (Part 3)
2025-10-21 12:00 - 13:00 (America/New_York)

Biomarkers in IgA Nephropathy
2025-12-03 12:00 - 13:00 (America/New_York)
Thank you for attending, we hope you enjoyed this webinar.
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Living Kidney Donation: One Solution for Patients with End-Stage Kidney Disease
Background: IgA nephropathy (IgAN) is the most prevalent glomerular disease worldwide and is associated with a poor prognosis. Development of new treatment strategies and approaches for early diagnosis is necessary. However, reliable biomarkers are needed for the noninvasive
diagnosis of this disease and to more fully delineate the risk of progression.1 The disease course is highly heterogeneous, which creates a strong need for reliable biomarkers for diagnosis, prognosis, and treatment monitoring.2 Finding biomarkers to improve the existing risk
prediction models or replace pathological indicators is important for clinical practice.3

Did You Know?

Currently, proteinuria, eGFR, and blood pressure are considered traditional biomarkers for IgA Nephropathy, while renal biopsy remains the gold standard diagnostic tool.4

Why Attend This Webinar?

This webinar will focus on the current biomarker landscape as well as novel biomarkers that are currently being studied. The webinar will also focus on why biomarkers are needed and what the unmet need is.

What You Will Learn:

Understand the key characteristics of an effective biomarker
Explore established biomarkers such as proteinuria, kidney biopsy, estimated glomerular filtration rate (eGFR), and blood pressure (BP).
Discover emerging diagnostic and prognostic biomarkers, including those found in
blood, urine, genetics, and the microbiota
Learn about specific biomarkers that indicate disease progression in IgA nephropathy (IgAN).
Explore the role and relevance of potential surrogate endpoints in clinical research and patient care.
Examine why biomarkers are essential in nephrology and the current unmet needs they aim to address.

References:

Suzuki H. Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis. Clin Exp Nephrol. 2019 2019 Jan;23(1):26-31
Zhixin Xu, et al. New biomarkers in IgA nephropathy. Clinical Immunology. 2025 May
Duan, ZY., Zhang, C., Chen, XM. et al. Blood and urine biomarkers of disease progression in IgA nephropathy. Biomark Res 12, 72 (2024). (accessed 4/28/25)
Selvaskandan H et al. Front Immunol. 2020;11:572754

Speaker

Pranav Garimella, MD
Associate Professor of Clinical Medicine and Nephrology, UC San Diego

Dr. Garimella is an Associate Professor of Clinical Medicine and Nephrology at UC San Diego. He is the founding Director of the UCSD PKD Center

Excellence as well as the Director of Acute Dialysis Services. He joined the American Kidney Fund as Chief Medical Officer in January 2025 as AKF’s first CMO. He received his training in India, Chicago, and completed his fellowship at Tufts University, training in clinical nephrology with a focus on polycystic kidney disease with Dr. Ron Perrone. Dr. Garimella is an established researcher whose research focus includes novel biomarkers of kidney function, cardiovascular disease, bone health and mortality. His research has been funded by the NIH, the Veterans Medical Research Foundation and UC San Diego. Dr. Garimella is also a trained epidemiologist who has authored several book chapters and over 110 articles in peer-reviewed journals including Annals of Internal Medicine, Journal of the American Society of Nephrology and Kidney International. He serves on the Editorial Board for Kidney Medicine, and as an as ad-hoc reviewer for multiple journals, including the New England Journal of Medicine, the Clinical Journal of the American Society of Nephrology, the Atherosclerosis, Thrombosis and Vascular Biology, American Journal of Kidney Diseases, and Clinical Nephrology. He has also received several awards for his research, clinical work, professionalism and teaching, and is a fellow of the American Society of Nephrology (FASN). He is also involved in initiatives to develop programs specifically targeted at minority populations in an effort to improve health literacy and potentially clinical outcomes.

Moderators

Sachin Hajarnis, PhD
Nephrology Medical Science Director

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Sachin Hajarnis, PhD is a Senior Medical Science Liaison at Otsuka Pharmaceuticals. Dr Hajarnis has a Bachelors and Masters in Life Sciences from University of Mumbai, India. He obtained a PhD in Biochemistry and Molecular Biology from Colorado State University. Dr Hajarnis joined the University of Texas Southwestern Medical school in Dallas, as a post-doctoral fellow in the department of Nephrology where he performed basic research on various aspects of Polycystic Kidney Disease (PKD). He continued his studies on the role of micro-RNAs in PKD as a Research Scientist for several years before joining his current position at Otsuka.

Marla Dallal, PharmD, RPH
Nephrology Senior Medical Science Liaison

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Marla Dallal, PharmD, RPH is a Medical Science Liaison at Otsuka Pharmaceutical Development and Commercialization covering Southern California. She earned her Doctor of Pharmacy degree from the University of Southern California, School of Pharmacy in Los Angeles. While in pharmacy school, Dr Dallal pursued various clinical internships within the acute care and ambulatory care settings at Cedars-Sinai Medical Center and Kaiser Permanente. Prior to joining Otsuka, Dr Dallal held various positions within Medical Affairs at Amgen Inc covering the cardiometabolic and nephrology therapeutic areas. She also served as a preceptor at Amgen Inc, where she instructed pharmacy students on Advanced Pharmacy Practice rotations. She is currently licensed as a pharmacist in the state of California with the National Association Board of Pharmacy.

Dr. Pranav Garimella is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc.Dr. Marla Dallal and Dr. Sachin Hajarnis are employees of Otsuka Pharmaceutical Development & Commercialization, Inc.

Disclaimer: The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional.
April 2025 US.CORP.X.25.00090

Registration

Related Resources
